Compare BYFC & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BYFC | MAIA |
|---|---|---|
| Founded | 1946 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.2M | 77.1M |
| IPO Year | 2013 | 2022 |
| Metric | BYFC | MAIA |
|---|---|---|
| Price | $9.60 | $1.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.5K | ★ 495.3K |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $184,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $190.80 | ★ N/A |
| Revenue Growth | ★ 18.71 | N/A |
| 52 Week Low | $5.51 | $0.87 |
| 52 Week High | $10.46 | $3.19 |
| Indicator | BYFC | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 58.89 | 55.69 |
| Support Level | $7.17 | $1.23 |
| Resistance Level | $10.46 | $1.46 |
| Average True Range (ATR) | 0.14 | 0.08 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 27.92 | 89.19 |
Broadway Financial Corp is active in the financial services domain. It is a savings and loan holding company in the United States. The Bank offers a variety of commercial real estate loan products, services, and depository accounts that support investments in affordable housing, small businesses, and nonprofit community facilities located within low-to-moderate income neighborhoods.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.